Drugs / ISTISOCICLIB
ISTISOCICLIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04718675 | Feb 2021 → Jan 2025 | non-Hodgkin lymphoma, ovarian serous cystadenocarcinoma, refractory malignant neoplasm | Kronos Bio | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISTISOCICLIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5199065 ↗ |
| Known as | KB-00130742 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5199065 ↗ |
| Known as | KB-0742 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04718675 ↗ |
| Known as | KB-130742 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5199065 ↗ |
| Known as | UB-18422 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5199065 ↗ |
| Modality | Small molecule | — CHEMBL5199065 ↗ |
| Route | Oral | “Oral capsules” NCT04718675 ↗ |